Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032

Overview

The Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market is expected to reach a 1,495.44 USD Million by 2032 and is projected to grow at a CAGR of 23.96% from 2025 to 2032.

Revenue, 2024 (USD Million)

495.06

Forecast, 2032 (USD Million)

1,495.44

CAGR, 2024 - 2032

23.96%

Report Coverage

Asia-Pacific

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market 2018-2032 USD Million

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market, Key Findings (2025-2032)

Market Growth and Projections:

Market Size (2024): 495.06 USD Million
Projected Market Size (2032): 1,495.44 USD Million
CAGR (2025-2032): 23.96%

Key Findings of Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market

The Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market was valued at 495.06 USD Million in 2024.
The Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market is likely to grow at a CAGR of 23.96% during the forecast period of 2024 to 2032.
In 2024, the Largest segment Molecular Test in Test Segment accounted for the largest share of the market with a revenue of 261.44 USD Million
The fastest growing segment Imaging Test in Test Segment grew Fastest with a CAGR of 27.46% during the forecast period from 2024 to 2032.

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Scope

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope

Product

Services and Softwares
Reagents and Kits
Instruments

Test

Thorecentesis
Sputum Cytology
Biopsy
Immunohistochemistry
Others
Imaging Test
Molecular Test

End User

Institutes and Research Centers
Academics
Hospital
Clinical Laboratories

Lung Cancer Type

Others
Large Cell Carcinoma
Lung Squamous CellCarcinoma (LUSC)
Lung Adenocarcinoma (LUAD)

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Data Coverage Insights

Study Period	2024-2032
Base Year	2020
Unit	Revenue in USD Million
Market Value in 2024	495.06 USD Million
Market Value in 2032	1,495.44 USD Million
CAGR (2025-2032)	23.96%
Historic Data	2016-2023
Market Segments Covered	Product,Test,End User,Lung Cancer Type

Regional Insights:

Leading Market (2024-2032): Asia-Pacific, leading in terms of revenue 495.06 USD Million in 2024
- Key Country: China, leading in terms of revenue with value of 161.63 USD Million in 2024.

Segments and Scope

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Product
- Instruments is the largest segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 221.59 USD Million in the year 2024.
- Reagents and Kits is the Fastest growing segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 23.50 % in forecast period 2025-2032.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Test
- Molecular Test is the largest segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 261.44 USD Million in the year 2024.
- Imaging Test is the Fastest growing segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 24.10 % in forecast period 2025-2032.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032, By End User
- Clinical Laboratories is the largest segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 173.87 USD Million in the year 2024.
- Clinical Laboratories is the Fastest growing segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 25.53 % in forecast period 2025-2032.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Lung Cancer Type
- Lung Adenocarcinoma (LUAD) is the largest segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 252.17 USD Million in the year 2024.
- Lung Adenocarcinoma (LUAD) is the Fastest growing segment in Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 24.44 % in forecast period 2025-2032.

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Company Share Analysis

Company Name
QIAGEN
Quest Diagnostics Incorporated
Abbott
General Electric
F. Hoffmann-La Roche Ltd.

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Company Profiling

Industry Related Reports

Asia-Pacific Breast Lesion Localization Methods Market

Europe Breast Lesion Localization Methods Market

North America Breast Lesion Localization Methods Market

Middle East & Africa Breast Lesion Localization Methods Market

South America Breast Lesion Localization Methods Market

Australia Breast Lesion Localization Methods Market

Belgium Breast Lesion Localization Methods Market

Brazil Breast Lesion Localization Methods Market

Canada Breast Lesion Localization Methods Market

China Breast Lesion Localization Methods Market

Frequently Asked Questions

What are the primary segments covered in the Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market?

The Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Product,Test,End User,Lung Cancer Type.

What is the current market size of the Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market?

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 495.06(Revenue in USD Million) in 2020.

What is the expected growth rate of the Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market?

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 23.96% during the forecast period of 2024 to 2032.

Which is the dominating segment in the Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market?

The Molecular Test segment is expected to dominate the Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market, holding a largest market share of 261.44 USD Million in 2024